Landgren, O., Diamond, B., Pandey, A., Hoffman, J., Coffey, D., Kaddoura, M., Walker, B., Bukhari, R., Diaz, C., Mompoint, S., Gutierrez, S., Koubek, K., Kowalski, A., Gallardo, L., Fernandes, S., Mira, S., Lopez, M. C., Armogan, M., Kazandjian, D. (2025). A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study). Blood. https://doi.org/10.1182/blood-2025-5775